The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures
IntroductionPrevious studies have demonstrated that programmed cell death-ligand 1 (PD-L1) serves as biomarker for poor prognosis and survival in advanced-stage non-small cell lung cancer (NSCLC) patients. However, the merit of PD-L1 expression to predict the prognosis of early stage NSCLC patients...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.567978/full |
id |
doaj-c9506e479b5a470f937b9637da9887d7 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tao Shi Shuai Zhu Hengjuan Guo Xiongfei Li Shikang Zhao Yanye Wang Xi Lei Dingzhi Huang Ling Peng Ziming Li Song Xu |
spellingShingle |
Tao Shi Shuai Zhu Hengjuan Guo Xiongfei Li Shikang Zhao Yanye Wang Xi Lei Dingzhi Huang Ling Peng Ziming Li Song Xu The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures Frontiers in Oncology PD-L1 NSCLC meta-analysis prognosis resection |
author_facet |
Tao Shi Shuai Zhu Hengjuan Guo Xiongfei Li Shikang Zhao Yanye Wang Xi Lei Dingzhi Huang Ling Peng Ziming Li Song Xu |
author_sort |
Tao Shi |
title |
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures |
title_short |
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures |
title_full |
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures |
title_fullStr |
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures |
title_full_unstemmed |
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures |
title_sort |
impact of programmed death-ligand 1 expression on the prognosis of early stage resected non-small cell lung cancer: a meta-analysis of literatures |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-02-01 |
description |
IntroductionPrevious studies have demonstrated that programmed cell death-ligand 1 (PD-L1) serves as biomarker for poor prognosis and survival in advanced-stage non-small cell lung cancer (NSCLC) patients. However, the merit of PD-L1 expression to predict the prognosis of early stage NSCLC patients who underwent complete resection remains controversial. In the present study, we performed a meta-analysis to investigate the relationship between PD-L1 expression and prognosis in patients with early stage resected NSCLC.MethodsElectronic databases, including PubMed, EMBASE, and the Cochrane Library, were searched until July 23 2020 for studies evaluating the expression of PD-L1 and the prognosis of resected NSCLCs. Hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS) were pooled and analyzed. Heterogeneity and publication bias analyses were also assessed.ResultsA total of 15 studies involving 3,790 patients were considered in the present meta-analysis. The pooled HR indicated that PD-L1 expression related to a much shorter DFS (HR = 1.56, 95% CI: 1.18–2.05, p < 0.01), as well a significantly worse OS (HR = 1.68, 95% CI: 1.29–2.18, p < 0.01). Furthermore, our analysis indicated that PD-L1 expression was significantly associated with gender (male vs. female: OR = 1.27, 95% CI:1.01–1.59, p = 0.038), histology (ADC vs. SCC: OR = 0.54, 95% CI:0.38–0.77, p = 0.001), TNM stage (I vs. II–III: OR = 0.45, 95% CI:0.34–0.60, p = 0.000), smoking status (Yes vs No: OR = 1.43, 95% CI:1.14–1.80, p = 0.002) and lymph node metastasis (N+ vs N−: OR = 1.97, 95% CI:1.26–3.08, p = 0.003).ConclusionsThe results of this meta-analysis suggest that PD-L1 expression predicts an unfavorable prognosis in early stage resected NSCLCs. The role of personalized anti-PD-L1/PD-1 immunotherapy in the adjuvant settings of resected NSCLC warrants further investigation. |
topic |
PD-L1 NSCLC meta-analysis prognosis resection |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.567978/full |
work_keys_str_mv |
AT taoshi theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT shuaizhu theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT hengjuanguo theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT xiongfeili theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT shikangzhao theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT yanyewang theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT xilei theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT dingzhihuang theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT lingpeng theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT zimingli theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT songxu theimpactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT taoshi impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT shuaizhu impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT hengjuanguo impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT xiongfeili impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT shikangzhao impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT yanyewang impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT xilei impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT dingzhihuang impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT lingpeng impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT zimingli impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures AT songxu impactofprogrammeddeathligand1expressionontheprognosisofearlystageresectednonsmallcelllungcancerametaanalysisofliteratures |
_version_ |
1724255177067724800 |
spelling |
doaj-c9506e479b5a470f937b9637da9887d72021-02-23T05:30:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-02-011110.3389/fonc.2021.567978567978The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of LiteraturesTao Shi0Shuai Zhu1Hengjuan Guo2Xiongfei Li3Shikang Zhao4Yanye Wang5Xi Lei6Dingzhi Huang7Ling Peng8Ziming Li9Song Xu10Precision Medicine Center, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Respiratory and Critical Care, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, ChinaDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, ChinaIntroductionPrevious studies have demonstrated that programmed cell death-ligand 1 (PD-L1) serves as biomarker for poor prognosis and survival in advanced-stage non-small cell lung cancer (NSCLC) patients. However, the merit of PD-L1 expression to predict the prognosis of early stage NSCLC patients who underwent complete resection remains controversial. In the present study, we performed a meta-analysis to investigate the relationship between PD-L1 expression and prognosis in patients with early stage resected NSCLC.MethodsElectronic databases, including PubMed, EMBASE, and the Cochrane Library, were searched until July 23 2020 for studies evaluating the expression of PD-L1 and the prognosis of resected NSCLCs. Hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS) were pooled and analyzed. Heterogeneity and publication bias analyses were also assessed.ResultsA total of 15 studies involving 3,790 patients were considered in the present meta-analysis. The pooled HR indicated that PD-L1 expression related to a much shorter DFS (HR = 1.56, 95% CI: 1.18–2.05, p < 0.01), as well a significantly worse OS (HR = 1.68, 95% CI: 1.29–2.18, p < 0.01). Furthermore, our analysis indicated that PD-L1 expression was significantly associated with gender (male vs. female: OR = 1.27, 95% CI:1.01–1.59, p = 0.038), histology (ADC vs. SCC: OR = 0.54, 95% CI:0.38–0.77, p = 0.001), TNM stage (I vs. II–III: OR = 0.45, 95% CI:0.34–0.60, p = 0.000), smoking status (Yes vs No: OR = 1.43, 95% CI:1.14–1.80, p = 0.002) and lymph node metastasis (N+ vs N−: OR = 1.97, 95% CI:1.26–3.08, p = 0.003).ConclusionsThe results of this meta-analysis suggest that PD-L1 expression predicts an unfavorable prognosis in early stage resected NSCLCs. The role of personalized anti-PD-L1/PD-1 immunotherapy in the adjuvant settings of resected NSCLC warrants further investigation.https://www.frontiersin.org/articles/10.3389/fonc.2021.567978/fullPD-L1NSCLCmeta-analysisprognosisresection |